Tocilizumab biosimilar (Fresenius kabi)

托珠单抗生物类似药 (Fresenius kabi)

Report date: 2026/03/06 20:02:51

Base Information

Drug NameTocilizumab biosimilar (Fresenius kabi)
Drug Alias Name托珠单抗生物仿制药 (Fresenius kabi)TyenneMSB-11456AT-220 (Arecor Therapeutics)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[7] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/09/15
Country/TerritoryCzechiaBulgariaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesLigand Pharmaceuticals IncFresenius Kabi Usa LlcUniversity Of Florida +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC07
Related LinksN/A